Gland Pharma Ltd.

NSE: GLAND BSE: 543245 SECTOR: Pharmaceuticals & Drugs

3864.9
-154.35 (-3.84%)
NSE: Today, 03:55 PM

Price Summary

Today's High

₹ 4078

Today's Low

₹ 3834.05

52 Week High

₹ 4172

52 Week Low

₹ 1700

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationAttractive
The stock is considerably attractive based on intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.

Company Essentials

Market Cap

63476.02 Cr.

Enterprise Value

62155.79 Cr.

No. of Shares

16.42 Cr.

P/E

63.67

P/B

10.15

Face Value

₹ 1

Div. Yield

0%

Book Value (TTM)

₹  380.79

CASH

1325.19 Cr.

DEBT

4.96 Cr.

Promoter Holding

58.14%

EPS (TTM)

₹  60.71

Sales Growth

28.81%

ROE

23.81 %

ROCE

30.68 %

Profit Growth

71.02 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Ratios

Sales Growth

1 Year28.81%
3 Year21.2%
5 Year21.52%

Profit Growth

1 Year71.02%
3 Year23.16%
5 Year29.86%

ROE%

1 Year23.81%
3 Year18.41%
5 Year19.52%

ROCE %

1 Year30.68%
3 Year26.4%
5 Year27.52%

Debt/Equity

0.0014

Price to Cash Flow

90.56

Interest Cover Ratio

139.243664717349

CFO/PAT (5 Yr. Avg.)

0.786763344986266

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2021 58.14 0
Mar 2021 58.25 0
Dec 2020 58.36 0
Sep 2018 96.08 0
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 23.1579063663838% for the Past 3 years.
  • The company has shown a good revenue growth of 21.1963002618893% for the Past 3 years.
  • Company has been maintaining healthy ROCE of 26.4027551432653% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 139.243664717349.
  • The Company has been maintaining an effective average operating margins of 36.5411851896229% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 7.92787648702172.
  • The company has a high promoter holding of 58.14%.

 Limitations

  • The company is trading at a high EV/EBITDA of 44.196.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2020 Mar 2021 Jun 2021
Net Sales 859.42 887.75 1153.9
Total Expenditure 595.19 560.03 717.6
Operating Profit 264.23 327.71 436.3
Other Income 35.13 47.21 61.84
Interest 1.16 1.02 1
Depreciation 24.97 24.92 25.28
Exceptional Items 0 0 0
Profit Before Tax 273.24 348.99 471.86
Tax 69.13 88.53 121.19
Profit After Tax 204.11 260.45 350.68
Adjusted EPS (Rs) 12.5 15.92 21.4

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 1347.87 1479.18 1619.94 2044.2 2633.24
Total Expenditure 845.63 854.19 1084.84 1337.89 1677.77
Operating Profit 502.23 624.99 535.11 706.31 955.47
Other Income 36.76 33.56 48.79 85.56 139.17
Interest 16.42 6.39 4.13 3.56 7.18
Depreciation 63.46 74.15 78.21 81.96 94.59
Exceptional Items 0 0 0 -20 0
Profit Before Tax 459.11 578.01 501.56 686.36 992.87
Tax 145.51 164.29 180.45 234.45 220.01
Net Profit 313.61 413.73 321.11 451.91 772.86
Adjusted EPS (Rs.) 202.39 267.01 207.24 291.65 49.88

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 15.49 15.5 15.5 15.5 15.5
Total Reserves 1661.57 2074.32 2394.93 2846.62 3630.74
Borrowings 56.54 5.92 5.49 4.96 4.07
Other N/C liabilities 65.41 124.63 133.88 122.83 76.71
Current liabilities 287.29 253.38 378.55 532.68 359.02
Total Liabilities 2086.31 2473.75 2928.34 3522.58 4086.04
Assets
Net Block 787.88 871.58 842.64 928.74 968.1
Capital WIP 202.1 161.15 198.88 123.16 188.47
Intangible WIP 0 0 0 0 0
Investments 0.17 0 0 0 0
Loans & Advances 21.63 29.42 33.89 111.89 81.52
Other N/C Assets 2.62 3.45 1.95 1.33 1.66
Current Assets 1071.9 1408.15 1850.98 2357.46 2846.29
Total Assets 2086.31 2473.75 2928.34 3522.58 4086.04
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit from operations 459.11 578.01 501.56 686.36 992.87
Adjustment 68.72 70.69 50.94 76.12 32.15
Changes in Assets & Liabilities -187.17 -10.86 -193.43 -353.95 -79.94
Tax Paid -116.56 -161.39 -157.14 -223.47 -244.14
Operating Cash Flow 224.09 476.46 201.93 185.06 700.94
Investing Cash Flow -15.78 -100.19 -358.57 -318.57 -760.97
Financing Cash Flow -92.9 -116.42 -3.59 -2.93 -6.87
Net Cash Flow 115.42 259.85 -160.24 -136.44 -66.9

Corporate Actions

Investors Details

PARTICULARS Sep 2018 Dec 2020 Mar 2021 Jun 2021
Promoters 96.08 58.36 58.25 58.14
fosun pharma industrial p...
PARTICULARS Sep 2018 Dec 2020 Mar 2021 Jun 2021
Public 3.92 18.1 18.63 19.32
gland celsus biochemicals...
PARTICULARS Sep 2018 Dec 2020 Mar 2021 Jun 2021
FII/DII 0 23.54 23.12 22.54
axis mutual fund trustee ...

Ratings & Research Reports

No Credit and Research reports exist for this company.
Report us

Company Presentations

Gland Pharma Stock Price Analysis and Quick Research Report. Is Gland Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Gland Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 700.935 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Gland Pharma has a Debt to Equity ratio of 0.0014 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Gland Pharma , the EPS growth was -82.8978528768087 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Gland Pharma has OPM of 36.2848430070939 % which is a good sign for profitability.
     
  • ROE: Gland Pharma have a healthy ROE of 23.8100490090365 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Gland Pharma

X